Lupin has increased its indirect ownership in Multicare Pharmaceuticals Philippines to 99.89% through its wholly owned Netherlands subsidiary, Nanomi B.V. The stake consolidation, effective July 01, 2026, was achieved via a share acquisition and a concurrent buyback process, strengthening the Indian pharmaceutical major's control over its Southeast Asian operations.

Transaction Details

Nanomi completed the acquisition of 11,794,497 shares from existing shareholders of Multicare Pharmaceuticals Philippines (MPPI) on July 01, 2026. Simultaneously, MPPI finalized a buy-back of 61,118 shares from two existing shareholders on the same date. A separate buy-back process for the remaining 30,559 shares is currently in progress.

Shareholding Structure

Following these transactions, Nanomi's shareholding in MPPI rose significantly from 56.28% to 99.89%. The following table summarizes the key changes in the ownership structure:

The disclosure was submitted to the National Stock Exchange of India and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Global pharmaceutical leader Lupin announced on June 26, 2026, that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets. The approval covers four strengths: 40 mg, 80 mg, 120 mg, and 160 mg. This regulatory milestone allows the company to offer alternative dosing options to healthcare providers and patients, potentially expanding access to treatment.

Approval Details and Reference Drug

The U.S. FDA has tentatively approved the 40 mg and 80 mg strengths as bioequivalent to the reference listed drug (RLD) Xtandi® Tablets, marketed by Astellas Pharma Inc., for the indications specified in the approved labeling. Lupin's inclusion of 120 mg and 160 mg strengths provides additional flexibility in dosing regimens beyond what is traditionally available with the reference drug.

The following table outlines the approved strengths and their respective reference drug details:

About Lupin Limited

Lupin Limited is headquartered in Mumbai, India, and distributes its products in over 100 markets globally. The company's portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It maintains a strong presence in India and the U.S. across various therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 manufacturing sites and 7 research centers worldwide, supported by a workforce of over 24,000 professionals. Through its subsidiaries—Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions—the firm focuses on improving patient health outcomes.